Patient-reported outcomes in acute leukemia: A roadmap for future research

European Journal of Haematology

Volumn 93, Issue 1, 2014, Pages 86-87

  Efficace, Fabio ^a   Breccia, Massimo ^b   Lo Coco, Francesco ^c,d  

^a GIMEMA Data Center   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PROGNOSIS; DISEASE SEVERITY; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PRIORITY JOURNAL; FEMALE; MALE; PSYCHOLOGY; QUALITY OF LIFE; SURVIVOR;

FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; QUALITY OF LIFE; SURVIVORS;

EID: 84902540058     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12337     Document Type: Letter

References (12)

1. Leunis A, Ken Redekop W, Uyl-de Groot CA, Löwenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014. doi: 10.1111/ejh.12324.
2. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-21.
3. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008;44:1497-506.
4. Messerer D, Engel J, Hasford J, et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica 2008;93:826-33.
5. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant 1997;20:307-15.
6. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009;10:865-71.
7. Efficace F, Innominato PF, Bjarnason G, et al. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2008;26:2020-6.
8. Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013;98:208-16.
9. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012;30:4249-55.
10. US Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration December, 2009 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
11. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013;309:814-22.
12. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-63.